French Glendon E. III sold $6K of LUNG
French Glendon E. III (President and CEO) sold 4,171 shares of Pulmonx Corp (LUNG) at $1.54 on 2026-06-01.
Insider selling is a modest, near-term sentiment input but not a fundamental catalyst by itself.
Pulmonx CEO French Glendon E. III sold 4,171 shares in an open-market transaction disclosed via Form 4.
Likely limited immediate impact; any effect is typically short-lived unless repeated or paired with other negative news.
Background
This is an SEC Form 4 insider transaction (officer/director) for Pulmonx Corp.
Why it matters
The disclosure provides incremental sentiment information; it does not include new operational, clinical, or financial developments.
Market relevance
Traders may monitor for follow-on insider activity, but this single sale is unlikely to be a standalone catalyst.
Market effects
For small-cap biotech/medical device names, routine insider sales can slightly affect sentiment but rarely reset sector expectations.
None.
None.
Alternative perspectives
An open-market sale can reflect diversification or liquidity needs and may not signal reduced confidence.
No 10b5-1 plan was indicated; without context (taxes, diversification, prior grants), the signal strength is ambiguous.
Key entities
- issuerPulmonx Corp
Subject of the Form 4 insider sale by its President and CEO.
- insiderFrench Glendon E. III
President and CEO who sold 4,171 shares at $1.54 on June 1, 2026.